Who are Placebo to ezetimibe/atorvastatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SPC ezetimibe/rosuvastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-ezetimibe-atorvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo to ezetimibe/atorvastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to ezetimibe/atorvastatin (Placebo to ezetimibe/atorvastatin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholesterol absorption inhibitor/HMG-CoA reductase inhibitor. Area: Cardiovascular.

phase 3 Cholesterol absorption inhibitor/HMG-CoA reductase inhibitor NPC1L1/HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to ezetimibe/atorvastatin (Placebo to ezetimibe/atorvastatin) — Organon and Co. Ezetimibe inhibits the absorption of cholesterol in the small intestine, while atorvastatin inhibits HMG-CoA reductase to reduce cholesterol production in the liver.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo to ezetimibe/atorvastatin TARGET	Placebo to ezetimibe/atorvastatin	Organon and Co	phase 3	Cholesterol absorption inhibitor/HMG-CoA reductase inhibitor	NPC1L1/HMG-CoA reductase
SPC ezetimibe/rosuvastatin	SPC ezetimibe/rosuvastatin	Sanofi	phase 3	Cholesterol absorption inhibitor/statin	NPC1L1/HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholesterol absorption inhibitor/HMG-CoA reductase inhibitor class)

Organon and Co · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to ezetimibe/atorvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-ezetimibe-atorvastatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab